去铁胺对脑出血后恢复轨迹的影响:i-DEF试验的事后分析
该研究为i-DEF试验的事后分析,纳入291例脑出血患者(安慰剂组145例、去铁胺组146例),评估去铁胺对改良Rankin量表恢复轨迹的影响。结果显示两组mRS 0-2分比例从第7天至第180天持续增加,去铁胺改变了恢复轨迹(交互P=0.0010),第90至180天去铁胺组改善(P=0.0001),安慰剂组无显著改善(P=0.3005)。
要点
- 脑出血后患者的功能恢复可持续至6个月,mRS 0-2分比例从第7天至第180天持续增加。
- 去铁胺组在第90至180天mRS评分改善(P=0.0001),安慰剂组无显著改善(P=0.3005)。
- 去铁胺似乎加速并改变了以mRS评估的恢复轨迹(交互P=0.0010)。
核心结论
- 大部分脑出血患者在发病后6个月内持续改善;去铁胺似乎加速并改变了以mRS评估的恢复轨迹。
研究设计与样本
- i-DEF试验的事后分析,该试验为多中心、随机、安慰剂对照、双盲、无效性设计、2期临床试验,本分析基于实际接受的治疗。
- 共纳入291例受试者进行分析(安慰剂组145例,去铁胺组146例)。
- 采用广义线性混合模型评估结局随时间的变化轨迹,并校正随机化变量、脑室内出血的存在及脑出血部位。
主要发现
- 两组mRS 0-2分患者比例从第7天至第180天持续增加(主效应模型中时间交互P<0.0001)。
- 去铁胺治疗改变了恢复轨迹(交互P=0.0010)。
- 第90天至第180天期间,去铁胺组改善(P=0.0001),而安慰剂组无显著改善(P=0.3005)。
关键数值与推荐
- 良好结局定义为mRS评分0-2分。
临床怎么用
- 未来的脑出血试验应评估90天后的结局,至少随访6个月。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on the trajectory of recovery and long-term functional outcomes after intracerebral hemorrhage (ICH). Most ICH trials have conventionally assessed outcomes at 3 months following the footsteps of ischemic stroke. The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period. We evaluated the trajectory of mRS among trial participants and examined the effect of deferoxamine on this trajectory. METHODS: We performed a post hoc analysis of the i-DEF trial, a multicenter, randomized, placebo-controlled, double-blind, futility-design, phase 2 clinical trial, based on the actual treatment received. Favorable outcome was defined as mRS score of 0-2. A generalized linear mixed model was used to evaluate the outcome trajectory over time, as well as whether the trajectory was altered by deferoxamine, after adjustments for randomization variables, presence of intraventricular hemorrhage, and ICH location. RESULTS: A total of 291 subjects were included in analysis (145 placebo and 146 deferoxamine). The proportion of patients with mRS score of 0-2 continually increased from day 7 to 180 in both groups (interaction P<0.0001 for time in main effects model), but treatment with deferoxamine favorably altered the trajectory (interaction P=0.0010). Between day 90 and 180, the deferoxamine group improved (P=0.0001), whereas there was not significant improvement in the placebo arm (P=0.3005). CONCLUSIONS: A large proportion of patients continue to improve up to 6 months after ICH. Future ICH trials should assess outcomes past 90 days for a minimum of 6 months. In i-DEF, treatment with deferoxamine seemed to accelerate and alter the trajectory of recovery as assessed by mRS. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02175225.
引用
- Foster L, Robinson L, Yeatts SD, et al. Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022. PMID: 35306827. doi:10.1161/STROKEAHA.121.037298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。